The epidemiology of secondary cancers in childhood cancer survivors has been unknown in Asian countries. Our aim is to assess the incidence and risk factors for secondary cancers through a nationwide survey in Japan.
A retrospective cohort study comprising 10,069 children who were diagnosed with cancer between 1980 and 2009 was conducted in 15 Japanese hospitals. The cumulative incidence rate was calculated using death as the competing risk and compared by the Gray method. The standardized incidence ratio (SIR) was defined as the ratio of the number of observed cancers divided by the number of expected cancers. The risk factors were analyzed using Cox regression analysis.
One hundred and twenty-eight patients (1.3 %) developed secondary cancers within a median follow-up of 8.4 years. The cumulative incidence rate was 1.1 % (95 % confidence interval [CI] 0.9–1.4) at 10 years and 2.6 % (95 % CI 2.1–3.3) at 20 years after primary cancer diagnosis. Sensitivity analysis, limited to 5-year survivors (n = 5,387), confirmed these low incidence rates. The SIR of secondary cancers was 12.1 (95 % CI 10.1–14.4). In the Cox analysis, the hazard ratios for secondary cancers were 3.81 (95 % CI 1.53–9.47) for retinoblastoma, 2.78 (95 % CI 1.44–5.38) for bone/soft tissue sarcomas, and 1.81 (95 % CI 1.16–2.83) for allogeneic stem cell transplantation.
The cumulative incidence of secondary cancers in children in Japan was not high; however, the SIR was relatively high. Retinoblastoma or sarcoma in addition to allogeneic stem cell transplantation were significant risk factors for secondary cancers.
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1HAV65K
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/21pyY4F
Can any cancer cell form another tumour, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new study finds, is both. Researchers at the University of Michigan Comprehensive Cancer Center looked at human ovarian…
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/21pyXxS
|Some Splendours, Some Miseries
‘The School Boy’ by William Blake came a familiar welcoming tone through the larynx of his literature teacher. The boy remained hypnotized on his teacher’s wise phizog. His teacher with his gesture and deep-insights would often bring in the whole …
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/21pyYBJ
|Oncogenic PTEN functions and models in T-cell malignancies
As truncated PTEN proteins undergo rapid degradation, exon 7 mutations are associated with lost or reduced PTEN expression. This clustered spectrum of mutations on exon 7 is an intriguing finding, as it is very specific to T-ALL. In other forms of …
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/21pyVGb
Conclusions Characterizing the expression of miR-146a and miR-155 and their functional role in tumor biology underlined significantly their proliferation and migration potential suggesting relevance as potential prognostic markers in HNSCC. (Source: Journal of Cancer Research and Clinical Oncology)
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1IwALJM
Liposomal anticancer agents can effectively deliver drugs to tumor lesions, but their therapeutic effects are enhanced in only limited number of patients. Appropriate biomarkers to identify responder patients to these liposomal agents will improve their treatment efficacies. We carried out pharmacological and histopathological analyses of mouse xenograft models bearing human ovarian cancers (Caov‐3, SK‐OV‐3, KURAMOCHI, and TOV‐112D) to correlate the therapeutic effects of doxorubicin‐encapsulated liposome (Doxil®) and histological characteristics linked to the enhanced permeability and retention effect. We next generated 111In‐encapsulated liposomes to examine their capacities to determine indications for Doxil® treatment by single‐photon emission computed tomography (SPECT…
from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1TowsXn